We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Valoarea tratamentului instilaţional adjuvant în cazul cancerului de vezică urinară stadiile Ta şi T1.
- Authors
Glück, G.; Stoica, R.; Neagoe, L.; Sinescu, I.
- Abstract
Purpose. To compare transurethral resection only with transurethral resection plus adjuvant instillational treatment for non-invasive (Ta, T1) bladder cancer. Patients and methods. Between 2000-april 2005, 185 patients with Ta and T1 bladder cancers were included in this study. The patients were divided in two groups: Group A including 81 patients who were treated (2000-2002) with transurethral resection of the bladder tumours (TURB). Follow up: 76-108 months (mean 86 months); Goup B including 104 patients with TURB,1 instillation with 50 mg of Epirubicin in the first six po hours. Follow up 44-80 months (mean 62 months). When we received the pathological report, the patients were divided, according to EAU protocols risk factors, in 3 categories: Low risk: 7 patients. They didn't receive any other treatment only follow up (cystoscopy, cytology) at 3 month, after 1 year, then every year. Medium risk: 45 patients: 29 without treatment, 13 with intravesical chemotherapy, 9 with BCG (according to their option). High risk: 53 patients, 41 receiving intravesical BCG. The follow up were performed every 3 months in the first year, 4 months in the 2nd year, 6 months in the 3rd and 4th year, than every year. Results. In group A, the percent of recurrencies according to the risk categories are: 30%, 37,5%, 58%. The total recurrence in group A is 44,4%. In group B, the percent of recurrencies are: 0%, 20,4%, 41,5%. The total recurrence is 29,8%. The benefit of 1 instillation with Epirubicin post-TURB is 10,4%, particulary for low risk group is 30%. Intravesical chemotherapy add 21,4 % benefit regarding recurrence; BCG add 22,4% benefit. The progression rate in group A are: 0%, 12,5%, 29%. The global progression is 17,2%. In the group B, the progression rate is: 0%, 6,8%, 17%. The global progression is 11,5%. Conclusions. The study indicated a significant benefit in favor of the adjuvant instillational treatment group, reducing the percent of tumor recurrence from 44,4% to 29,8% (difference is 14,6%); regarding the progression rate the benefit is 5,7% (from 17,2% to 11,5%).
- Subjects
ADJUTANTS; BLADDER cancer treatment; TRANSURETHRAL prostatectomy; COMPARATIVE studies; BLADDER tumors; CYSTOSCOPY; CYTOLOGY; CANCER chemotherapy; CYSTOMETRY
- Publication
Romanian Journal of Urology, 2009, Vol 8, Issue 3, p37
- ISSN
1223-0650
- Publication type
Article